Navin Fluorine to meet Analysts/Investors on Sept 21, 2026
Navin Fluorine will interact with analysts and investors on September 21, 2026. The company reported Q1 FY27 consolidated revenue of ₹1,045.1 Cr, up 44% YoY. Operating EBITDA rose 73% YoY to ₹357.1 Cr. Significant capex includes ₹125 Cr for cGMP4 Phase II by Q4 FY27 and ₹90 Cr for Advanced Materials by Q2 FY28.
The announcement includes strong financial results with significant year-on-year growth, alongside details of substantial future capital expenditure and strategic initiatives like developing advanced materials. This combination of current performance and future growth drivers is likely to have a high impact on investor perception.
The company's Q1 FY27 results show strong year-on-year growth in revenue, EBITDA, and PBT. Positive outlook is further supported by ongoing capex plans and incubation of new business verticals, indicating growth potential. The investor meet also suggests proactive engagement with the market.
Navin Fluorine International Limited has announced its schedule for interactions with Analysts and Institutional Investors. The company officials will be meeting with participants on September 21, 2026, for the Anand Rathi: G-200 Summit 2026 – Bharat - The Next Engine of Global Growth. This interaction will be held physically and will include one-on-one and group meetings.
The company has also provided an investor presentation that forms the basis of these discussions. The discussions will be centered around publicly available information, and the company has noted that changes may occur due to exigencies. This intimation is also available on the company's official website, www.nfil.in.
In addition to the investor meet, the company has released its Q1 FY27 financial performance highlights. Consolidated Net Revenue from Operations stood at ₹1,045.1 Cr, marking a 44% year-on-year increase and an 11% quarter-on-quarter rise. Operating EBITDA grew by 73% YoY to ₹357.1 Cr, with an Operating EBITDA Margin of 34.2%. Operating PBT increased by 101% YoY to ₹283.3 Cr. The company also detailed significant capex plans, including an additional HFC capacity of up to 15,000 MTPA of R32, expected to be commissioned by Q3FY27, and Phase II of cGMP4 capex of ₹125 Cr, targeted for Q4 FY27. Furthermore, a new Advanced Materials vertical is being incubated with a capex of ₹90 Crs, expected by Q2 FY28, and Chemours project capex of ₹120 Crs, with initial commercial capacity targeted by Q2 FY27.
What to do with a filing like this
Navin Fluorine International Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Navin Fluorine International Limited. Read the original for the full detail.